Security key
70424C203
PaxMedica, Inc. - Common Stock, par value $0.0001 per share (PXMD)
CUSIP: 70424C203
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 58
- Total 13F value
- $12
- Share change
- -126,952
- SEC-reported price per share
- $0.21
- Number of holders
- 1
- Value change
- -$64,713
- Number of sells
- 7
- Shares outstanding
- 9,949,495
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
1
Top holders
1
PXMD full security history
Ownership snapshot
Full 13F holder table
Kuvatris Therapeutics, Inc. SEC filings
Kuvatris Therapeutics, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of PXMD - PaxMedica, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
TardiMed Sciences LLC
Disclosed value leader
TardiMed Sciences LLC
Comparable rows
0/15
Latest evidence
31 Mar 2024
3/4/5
13F
Highest disclosed value: $1,355,830
15 rows are not safely comparable across share classes.
Showing 1-6 of 15 holder rows.
Quick read
TardiMed Sciences LLC has the largest disclosed position value at $1.36M.
0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens TardiMed Sciences LLC's linked filing trail.
Disclosed position value
Top 5
TardiMed Sciences LLC
$1.36M
Michael Derby
$84.5K
Howard J. Weisman
$24K
Souders Financial Advisors
$20.4K
Virtu Financial LLC
$19K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TardiMed Sciences LLC |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$1,355,830
7,336,745 shares
|
— | 30 Aug 2022 |
| Michael Derby |
3/4/5
10%+ Owner
|
—
denominator unverified
|
$84,495
457,224 shares
|
— | 27 Nov 2023 |
| Howard J. Weisman |
3/4/5
Chief Executive Officer, Director
|
—
denominator unverified
|
$23,976
34,748 shares
|
— | 12 Mar 2024 |
| Souders Financial Advisors |
13F
Company
|
—
denominator unverified
|
$20,400
40,000 shares
|
— | 31 Mar 2024 |
| Virtu Financial LLC |
13F
Company
|
—
denominator unverified
|
$19,000
37,315 shares
|
— | 31 Mar 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
Company
|
—
denominator unverified
|
$13,306
26,091 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
1
Shares
58
Rows available
1
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
8
Q2 2024 holders
1
Holder diff
-7
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|